SAN RAMON, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) --  CooperCompanies (Nasdaq: COO), today announced it has closed the acquisition of select Cook Medical assets focused primarily on the obstetrics, doppler monitoring, and gynecology surgery markets. The purchase price was $300 million with $200 million paid at closing and the remaining $100 million to be paid in two $50 million annual installments.   “This acquisition is a fantastic strategic fit for CooperSurgical,” said Al White, President and CEO of CooperCompanies.

加利福尼亚州圣拉蒙，2023年11月1日（GLOBE NEWSWIRE）-库珀公司（纳斯达克股票代码：首席运营官）今天宣布已关闭收购主要集中在产科，多普勒监测和妇科手术的精选库克医疗资产市场。购买价格为3亿美元，截止时支付2亿美元，其余1亿美元将以每年5000万美元的安装支付。CooperCompanies总裁兼首席执行官Al White说：“这次收购对于合作医疗来说是一个非常棒的战略契合。

“The acquired products are highly synergistic with CooperSurgical’s existing portfolio of medical devices and strengthen CooperSurgical’s position as a leading global fertility and women’s health company.” The assets being acquired are primarily minimally invasive medical devices including the Bakri® Postpartum Balloon, Cook’s Cervical Ripening Balloon, the Doppler Blood Flow Monitor portfolio, and select surgical products.

“收购后的产品与CooperSurgical现有的医疗器械组合高度协同，并加强了CooperSurgical作为全球领先的生育和女性健康公司的地位。”收购的资产主要是微创医疗器械，包括Bakri®产后气球，Cook's宫颈成熟气球，多普勒血流监测仪组合，并选择手术产品。

The acquired assets generated approximately $56 million in trailing twelve-months revenue as of September 30, 2023. As part of Cooper’s fiscal year 2024, revenues from this transaction are expected to grow 5-7% year-over-year in constant currency. Excluding one-time charges and deal-related amortization, the transaction is expected to be accretive to non-GAAP gross and operating margins and accretive to non-GAAP earnings per share by approximately $0.20.

截至2023年9月30日，收购后的资产在过去12个月的收入中产生了约5600万美元。作为库珀2024财年的一部分，本次交易的收入预计将以恒定货币逐年增长5-7%。不包括一次性费用和与交易有关的分摊，该交易预计将增加非GAAP的总额和经营利润率，并增加非GAAP的每股收益约0.20美元。

Cooper will report these assets as part of its Office and Surgical category within the CooperSurgical business beginning in its fiscal first quarter of 2024. This transaction does not include any of the fertility products contemplated in the original deal announced on February 7, 2022. Citigroup Global Markets Inc.

库珀将从2024年第一季度开始在合作业务中报告这些资产作为其办公室和外科类别的一部分。该交易不包括2022年2月7日宣布的原始交易中考虑的任何生育产品。Citigroup Global Markets Inc。

served as financial advisor to Cooper. About CooperCompaniesCooperCom.

担任库珀的财务顾问。关于CoopercompanieScooperm。